FindTrial
Sign In

Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Resected Hepatocellular Carcinoma Recurrence Surveillance (CCGLC-015)

Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Resected Hepatocellular Carcinoma Recurrence Surveillance (CCGLC-015)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500099403
Enrollment
Unknown
Registered
2025-03-24
Start date
2025-04-01
Completion date
Unknown
Last updated
2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma,HCC

Interventions

mt-ctDNA:None

Sponsors

Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients with hepatocellular carcinoma (HCC) deemed operable by the hepatobiliary tumor multidisciplinary team (MDT); 2.Expected survival time of 12 weeks or more; 3.Signed informed consent form and ability to comply with the study visits and related procedures as stipulated in the protocol; 4.Age > 18;

Exclusion criteria

Exclusion criteria: 1.Patients with other active tumors or severe complications; 2.Insufficient tumor tissue for MRD detection;

Design outcomes

Primary

MeasureTime frame
Progression-free survival;—

Secondary

MeasureTime frame
Overall survival;Changes in circulating tumor DNA (ctDNA) levels;Changes in tumor markers (AFP, PIVKA);Imaging findings;—

Countries

China

Contacts

Public ContactZeyang Ding

Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology

zyding@tjh.timu.edu.cn+86 13407156200

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026